| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| Other Sizes |
| Targets |
4-Bromo-1H-imidazole has been found to exhibit potent biological activity, particularly as an inhibitor of protein kinases. It has been shown to inhibit the activity of several kinases, including glycogen synthase kinase-3β (GSK-3β), cyclin-dependent kinase 2 (CDK2), and mitogen-activated protein kinase kinase 1 (MEK1). The compound also interacts with myoglobin by forming hydrogen bonds and electrostatic interactions.
|
|---|---|
| ln Vitro |
utilized as crucial starting materials for the production of organic synthesis, insecticides, medications, dyes, and other products.
In vitro, 4-bromo-1H-imidazole exhibits antimicrobial activity against various pathogens, including bacteria and fungi. It has been shown to have significant effects on pesticide activity due to its ability to bind to enzymes such as acetylcholinesterase. The compound is a biochemical reagent used for studying imidazole derivatives and their biological activity. As a protein kinase inhibitor, it can be used in cell signaling research. |
| ln Vivo |
In vivo data for 4-bromo-1H-imidazole as a therapeutic agent are limited. The compound has been studied for its potential as an antimicrobial and protein kinase inhibitor, but specific in vivo efficacy and pharmacokinetic data are not well-documented. Its in vivo relevance is primarily indirect, through the biological activities of the final pharmaceutical compounds derived from its imidazole scaffold.
|
| Enzyme Assay |
For in vitro enzyme inhibition assays, 4-bromo-1H-imidazole is evaluated for kinase inhibitory activity against GSK-3β, CDK2, and MEK1. Standard protocols involve incubating the compound with recombinant kinase enzymes and measuring kinase activity using luminescent or radiometric detection. The compound (0.01-100 µM) is pre-incubated with the enzyme and ATP before substrate addition. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based experiments, 4-bromo-1H-imidazole is evaluated for antimicrobial activity against various pathogens. Broth microdilution methods are used to determine the minimum inhibitory concentration (MIC) against bacteria and fungi. The compound can also be evaluated for its effects on cell signaling pathways in mammalian cells. Cells are treated with the compound at various concentrations and kinase activity or downstream signaling is measured by western blot.
|
| Animal Protocol |
In vivo animal studies for 4-bromo-1H-imidazole are limited. For potential antimicrobial or anticancer candidates derived from this scaffold, efficacy studies would typically be performed in mouse models of infection or cancer. Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection, with measurement of pathogen load, tumor volume, or survival as endpoints. Specific protocols for this compound are not available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 4-bromo-1H-imidazole are not extensively characterized. The compound has a molecular weight of 146.98 g/mol, which is favorable for oral bioavailability. The bromine atom may influence metabolic stability and lipophilicity. As an imidazole derivative, it is expected to have reasonable membrane permeability. Empirical pharmacokinetic data are not available in the public literature.
|
| Toxicity/Toxicokinetics |
4-Bromo-1H-imidazole is a research chemical and should be handled with appropriate laboratory safety precautions. As a brominated compound, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a fume hood.
|
| Additional Infomation |
4-Bromo-1H-imidazole (CAS 2302-25-2) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are as a versatile building block for organic synthesis and as a biochemical reagent for studying imidazole derivatives. The compound exhibits antimicrobial activity and inhibits protein kinases including GSK-3β, CDK2, and MEK1. No clinical trials or approved indications exist for this compound.
|
| Molecular Formula |
C3H3BRN2
|
|---|---|
| Molecular Weight |
146.97
|
| Exact Mass |
145.947
|
| CAS # |
2302-25-2
|
| PubChem CID |
96125
|
| Appearance |
White to off-white solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
324.7±15.0 °C at 760 mmHg
|
| Melting Point |
131-135 °C(lit.)
|
| Flash Point |
150.2±20.4 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.602
|
| LogP |
0.97
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
6
|
| Complexity |
48.1
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C(Br)NC=N1
|
| InChi Key |
FHZALEJIENDROK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C3H3BrN2/c4-3-1-5-2-6-3/h1-2H,(H,5,6)
|
| Chemical Name |
5-bromo-1H-imidazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (680.41 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (17.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (17.01 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (17.01 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.8041 mL | 34.0205 mL | 68.0411 mL | |
| 5 mM | 1.3608 mL | 6.8041 mL | 13.6082 mL | |
| 10 mM | 0.6804 mL | 3.4021 mL | 6.8041 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
